Developer docs
API playgroundTry for free, no card

Search company profiles

Immunome

Full company profile

uuid0000ygw

Namestring
Immunome
Legal namestring
Immunome, Inc.
Websiteurl
immunome.com
Company typeenum
Public
Founded yearint
2020
Descriptiontext

Immunome, Inc. is a clinical-stage biopharmaceutical company headquartered in Bothell, Washington (with intellectual-property and legal offices in Exton, Pennsylvania), publicly traded on NASDAQ under the ticker IMNM. The company develops targeted cancer therapies built on three technology pillars: antibody-drug conjugates (ADCs), radioligand therapies, and small-molecule gamma-secretase inhibitors, with a deliberate focus on novel or underexplored biological targets rather than the HER2/CLDN18.2/HER3 targets that dominate the ADC field. Its lead asset is varegacestat (AL102), an oral once-daily gamma-secretase inhibitor that completed Phase 3 (RINGSIDE) with an 84% reduction in disease-progression risk versus placebo in desmoid tumors; an NDA was submitted in April 2026 and accepted by the FDA in July 2026 (PDUFA April 28, 2027). The pipeline behind varegacestat includes IM-1021, a ROR1-targeted ADC incorporating a proprietary camptothecin-derived HC74 payload now in Phase 1; IM-3050, an FAP-targeted lutetium-177 radioligand that targets a receptor expressed in roughly 75% of solid tumors and entered Phase 1 in mid-2026; IM-1617, an ADC against an undisclosed receptor tyrosine kinase preferentially expressed in colorectal, breast, ovarian, and NSCLC tumors; and two preclinical ADC candidates (IM-1335, IM-1340).

Immunome is pre-commercial — trailing-twelve-month revenue was $4.0 million as of Q1 2026 and the FY2025 net loss was $212.4 million — with all value-creation to date driven by R&D milestones and equity financings rather than product sales. Total disclosed funding exceeds $1.113 billion, most recently via a $400 million public offering priced in December 2025, leaving a cash position of $582.7M–$653.5M that management states is sufficient to fund operations into 2028. The company plans to commercialize varegacestat (if approved) through a rare-disease specialty model: specialty pharmacies, hospital and cancer-center GPO contracts, and a field-based medical science liaison and sales team now being assembled. Customer segments are concentrated in rare oncology (desmoid tumors, ~1,000–1,650 new U.S. cases per year and an estimated $1B addressable opportunity) and broader solid-tumor oncology once the ADC and radioligand programs advance. Five Buy/Overweight initiations from major sell-side firms (H.C. Wainwright, Barclays, Truist, Guggenheim, Evercore ISI) in 2026 reflect analyst confidence in both the near-term varegacestat launch and the longer-duration platform optionality.

Short descriptiontext

Immunome is a clinical-stage biopharmaceutical company developing targeted cancer therapies, including ADCs, radioligand therapies, and small-molecule inhibitors, with lead asset varegacestat under FDA review for desmoid tumors and a broader solid-tumor pipeline in early-stage trials.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
251–500
akta.pro rankint
HeadquartersBothell, United States
HQ citystring
Bothell
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
targeted cancer therapy, antibody-drug conjugates, radioligand therapy, oncology drug development, gamma-secretase inhibitor
Industry3 codes
PRIMARYHLAAAAAE
Antibody-Drug Conjugates (ADCs) & Antibody Conjugates
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAAIAB
Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAIAGAB
Therapeutic Radiopharmaceuticals (Radioligand/Targeted Radionuclide Therapy)
Healthcare & Life Sciences/Pharmaceuticals/Radiopharmaceuticals & Nuclear Medicine
NAICS code1 code
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Biological Products, (No Disgnostic Substances)2836
Product category
Oncology Therapeutics
Social media profiles2 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Pharmaceutical Product Sales
TypeOne Time License
Description

Revenue from potential future sales of approved drugs, starting with varegacestat for desmoid tumors. Company is building commercial infrastructure including sales team and medical affairs for anticipated launch. Currently pre-revenue with only $4.0 million TTM revenue reported in 2026.

pharmiweb.com
2Asset Acquisition Income
TypeOne Time License
Description

Income from acquired antibody assets that enhance targeted cancer therapy portfolio, including 28 antibodies from Atreca acquisition for $5.5 million upfront with potential milestone payments.

investors.immunome.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Technology or R&D, Marketing or Sales, Operations
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Immunome is a clinical-stage oncology company developing a portfolio of targeted cancer therapies, including antibody-drug conjugates (ADCs), radioligand therapies, and small molecule gamma-secretase inhibitors. Lead asset varegacestat (AL102) targets desmoid tumors with NDA accepted by the FDA, while pipeline programs (IM-1021, IM-3050, IM-1617, IM-1340, IM-1335) target various solid tumor antigens including ROR1 and FAP.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • 84% reduction in risk of disease progression or death (HR=0.16, p<0.0001) vs placebo in Phase 3 RINGSIDE trial for desmoid tumors
+5 more records
Product overview1 text field

Immunome is a clinical-stage oncology company developing a portfolio of targeted cancer therapies. The company's pipeline includes near-term opportunities (Varegacestat, a Phase 3 gamma secretase inhibitor for desmoid tumors with NDA submitted to FDA) and mid-term opportunities (IM-1021, a ROR1-targeted ADC in Phase 1, and IM-3050, an FAP-targeted radioligand therapy in Phase 1). Preclinical programs include three ADC candidates (IM-1617, IM-1340, IM-1335) targeting undisclosed solid tumor antigens. The company leverages expertise in antibody-drug conjugates, radioligand therapies, and small molecules, with team members having contributed to development of ADCETRIS, PADCEV, TIVDAK, and TUKYSA.

Product and service6 records
1Varegacestat (AL102)
CategoryClinical-stage therapeutic
Description

An investigational once-daily oral gamma-secretase inhibitor (GSI) for the treatment of patients with progressing desmoid tumors. Completed Phase 3 RINGSIDE trial showing 84% reduction in risk of disease progression or death versus placebo; FDA NDA accepted with PDUFA date of April 28, 2027.

2IM-1021 (ROR1 Antibody-Drug Conjugate)
CategoryClinical-stage therapeutic
Description

A ROR1-targeted ADC optimized for ADC-mediated killing of ROR1 positive tumor cells, incorporating a proprietary camptothecin derivative payload (HC74) with cleavable linker and drug-antibody ratio of 8. In Phase 1 trial for liquid and solid tumors.

3IM-3050 (FAP Radioligand Therapy)
CategoryClinical-stage therapeutic
Description

An FAP-targeted radioligand therapy designed to deliver radioactive lutetium-177 directly to FAP-expressing cancer-associated fibroblasts in solid tumors. Incorporates small molecule FAP-specific ligand with albumin-binding domain for improved tumor retention. FAP expressed in approximately 75% of solid tumors.

4IM-1617 (Solid Tumor ADC)
CategoryPreclinical-stage therapeutic
Description

An ADC targeting an undisclosed receptor tyrosine kinase preferentially expressed in solid tumors including colorectal cancer, breast, ovarian, and non-small cell lung cancer. Mediates immune cell exclusion providing secondary mechanism of action. In Phase 1 trial.

5IM-1340 (Solid Tumor ADC Candidate)
CategoryPreclinical-stage therapeutic
Description

An ADC targeting a transport receptor with unique tumor expression profile spanning neuroendocrine tumors and other solid tumors. Demonstrated robust preclinical efficacy with regressions following single dose in tumor models.

6IM-1335 (Solid Tumor ADC Candidate)
CategoryPreclinical-stage therapeutic
Description

A potential best-in-class ADC for solid tumors designed to overcome limitations of a prior discontinued ADC against the same target. Shows efficacy in preclinical models with TOP1 payload class toxicity profile in non-human primates.

Scale indicator10 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
1Atreca, Inc.
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-05-20
Description

Immunome completed purchase of antibodies and related assets from Atreca, Inc. for $5.5 million upfront with additional milestone payments possible. Acquisition includes 28 antibodies and related materials enhancing Immunome's targeted cancer therapy portfolio. This acquisition was announced December 2023 and closed in May 2024.

investors.immunome.com
Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight7 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Clinical-stage ADC developer using proprietary payload platforms (Dolasynthen, Afucosylated antibodies) to target solid tumors. Directly comparable in business model, stage, and therapeutic focus on differentiated ADC payloads.

TypeDirect peer
Description

Clinical-stage oncology biotech developing targeted therapies for women's cancers. Kinney Horn (Immunome's CBO) was previously CBO at Olema, and both companies share similar size, stage, and capital markets profile as small-cap clinical oncology developers.

TypeBroad incumbent
Description

Commercial-stage radiopharmaceutical company with multiple approved products (Illuccix) and a pipeline of radioligand therapies. Comparable in the therapeutic radiopharmaceutical category, though with greater scale and geographic reach.

TypeBroad incumbent
Description

Radiopharmaceutical company with commercial products (Pylarify, Definity) and a pipeline of targeted radioligand therapies. Comparable as a more established player in the same radiopharmaceutical oncology space as Immunome's IM-3050.

TypeDirect peer
Description

Clinical-stage oncology biotech developing antibody-based therapeutics including ADCs and bispecifics. Bob Lechleider (Immunome's CMO) previously held roles at MacroGenics, and both companies pursue similar solid tumor ADC targets.

TypeEmerging player
Description

Clinical-stage oncology company developing engineered toxin bodies (ETBs) for cancer treatment. Jack Higgins (Immunome's CSO) previously spent 11 years at Molecular Templates as Chief Development Sciences Officer, providing direct organizational overlap.

TypeBroad incumbent
Description

Seagen developed and commercialized ADCETRIS, PADCEV, and TIVDAK, and was acquired by Pfizer for $43B in 2023. Immunome's leadership team and technology platform have direct lineage from Seagen, making it the closest functional and organizational peer.

TypeBroad incumbent
Description

ADC-focused biotech acquired by AbbVie for $10.1B in 2024. Developed Elahere (mirvetuximab soravtansine), the first FDA-approved ADC for ovarian cancer. Comparable as a specialist ADC developer with commercialized products in oncology.

TypeBroad incumbent
Description

Radiopharmaceutical company acquired by Eli Lilly for $1.4B in 2023, developing targeted radioligand therapies for cancer. Directly comparable to Immunome's IM-3050 FAP-targeted radioligand therapy program in technology category.

TypeBroad incumbent
Description

Japanese pharmaceutical leader with a major ADC franchise (Enhertu, Datroway) developed in partnership with AstraZeneca. Comparable as a major ADC innovator targeting solid tumors with TOP1-payload technology, though at substantially greater scale.

Market position
Strengths3 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds22 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors11 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Immunome

Oncology Therapeuticsimmunome.com

Immunome is a clinical-stage biopharmaceutical company developing targeted cancer therapies, including ADCs, radioligand therapies, and small-molecule inhibitors, with lead asset varegacestat under FDA review for desmoid tumors and a broader solid-tumor pipeline in early-stage trials.

What Immunome does

Immunome, Inc. is a clinical-stage biopharmaceutical company headquartered in Bothell, Washington (with intellectual-property and legal offices in Exton, Pennsylvania), publicly traded on NASDAQ under the ticker IMNM. The company develops targeted cancer therapies built on three technology pillars: antibody-drug conjugates (ADCs), radioligand therapies, and small-molecule gamma-secretase inhibitors, with a deliberate focus on novel or underexplored biological targets rather than the HER2/CLDN18.2/HER3 targets that dominate the ADC field. Its lead asset is varegacestat (AL102), an oral once-daily gamma-secretase inhibitor that completed Phase 3 (RINGSIDE) with an 84% reduction in disease-progression risk versus placebo in desmoid tumors; an NDA was submitted in April 2026 and accepted by the FDA in July 2026 (PDUFA April 28, 2027). The pipeline behind varegacestat includes IM-1021, a ROR1-targeted ADC incorporating a proprietary camptothecin-derived HC74 payload now in Phase 1; IM-3050, an FAP-targeted lutetium-177 radioligand that targets a receptor expressed in roughly 75% of solid tumors and entered Phase 1 in mid-2026; IM-1617, an ADC against an undisclosed receptor tyrosine kinase preferentially expressed in colorectal, breast, ovarian, and NSCLC tumors; and two preclinical ADC candidates (IM-1335, IM-1340).

Immunome is pre-commercial — trailing-twelve-month revenue was $4.0 million as of Q1 2026 and the FY2025 net loss was $212.4 million — with all value-creation to date driven by R&D milestones and equity financings rather than product sales. Total disclosed funding exceeds $1.113 billion, most recently via a $400 million public offering priced in December 2025, leaving a cash position of $582.7M–$653.5M that management states is sufficient to fund operations into 2028. The company plans to commercialize varegacestat (if approved) through a rare-disease specialty model: specialty pharmacies, hospital and cancer-center GPO contracts, and a field-based medical science liaison and sales team now being assembled. Customer segments are concentrated in rare oncology (desmoid tumors, ~1,000–1,650 new U.S. cases per year and an estimated $1B addressable opportunity) and broader solid-tumor oncology once the ADC and radioligand programs advance. Five Buy/Overweight initiations from major sell-side firms (H.C. Wainwright, Barclays, Truist, Guggenheim, Evercore ISI) in 2026 reflect analyst confidence in both the near-term varegacestat launch and the longer-duration platform optionality.

Immunome firmographics

Firmographics
Name
Immunome
Legal name
Immunome, Inc.
Website
https://immunome.com
Company type
Public
Founded year
2020
Operating status
Operating
Headcount range
251–500 employees
Short description
Immunome is a clinical-stage biopharmaceutical company developing targeted cancer therapies, including ADCs, radioligand therapies, and small-molecule inhibitors, with lead asset varegacestat under FDA review for desmoid tumors and a broader solid-tumor pipeline in early-stage trials.
Ownership category
akta.pro rank

Immunome industry classification

Industry
Product category
Oncology Therapeutics
NAICS
Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAAAAE
Antibody-Drug Conjugates (ADCs) & Antibody Conjugates
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAAIAB
Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAIAGAB
Therapeutic Radiopharmaceuticals (Radioligand/Targeted Radionuclide Therapy)
Healthcare & Life Sciences/Pharmaceuticals/Radiopharmaceuticals & Nuclear Medicine

Keywords

  • Targeted cancer therapy
  • Antibody-drug conjugates
  • Radioligand therapy
  • Oncology drug development
  • Gamma-secretase inhibitor

Where Immunome is headquartered

Location

Headquarters

HQ city
Bothell
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Immunome business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Marketing or Sales, Operations

Revenue model

  1. Pharmaceutical Product Sales: Revenue from potential future sales of approved drugs, starting with varegacestat for desmoid tumors. Company is building commercial infrastructure including sales team and medical affairs for anticipated launch. Currently pre-revenue with only $4.0 million TTM revenue reported in 2026.
  2. Asset Acquisition Income: Income from acquired antibody assets that enhance targeted cancer therapy portfolio, including 28 antibodies from Atreca acquisition for $5.5 million upfront with potential milestone payments.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels4 records

Immunome product offering

Product offering

Core offering

Immunome is a clinical-stage oncology company developing a portfolio of targeted cancer therapies, including antibody-drug conjugates (ADCs), radioligand therapies, and small molecule gamma-secretase inhibitors. Lead asset varegacestat (AL102) targets desmoid tumors with NDA accepted by the FDA, while pipeline programs (IM-1021, IM-3050, IM-1617, IM-1340, IM-1335) target various solid tumor antigens including ROR1 and FAP.

Product overview

Immunome is a clinical-stage oncology company developing a portfolio of targeted cancer therapies. The company's pipeline includes near-term opportunities (Varegacestat, a Phase 3 gamma secretase inhibitor for desmoid tumors with NDA submitted to FDA) and mid-term opportunities (IM-1021, a ROR1-targeted ADC in Phase 1, and IM-3050, an FAP-targeted radioligand therapy in Phase 1). Preclinical programs include three ADC candidates (IM-1617, IM-1340, IM-1335) targeting undisclosed solid tumor antigens. The company leverages expertise in antibody-drug conjugates, radioligand therapies, and small molecules, with team members having contributed to development of ADCETRIS, PADCEV, TIVDAK, and TUKYSA.

Differentiator

Problem solved

Functional benefit

Products and services

  • Varegacestat (AL102) An investigational once-daily oral gamma-secretase inhibitor (GSI) for the treatment of patients with progressing desmoid tumors. Completed Phase 3 RINGSIDE trial showing 84% reduction in risk of disease progression or death versus placebo; FDA NDA accepted with PDUFA date of April 28, 2027.
  • IM-1021 (ROR1 Antibody-Drug Conjugate) A ROR1-targeted ADC optimized for ADC-mediated killing of ROR1 positive tumor cells, incorporating a proprietary camptothecin derivative payload (HC74) with cleavable linker and drug-antibody ratio of 8. In Phase 1 trial for liquid and solid tumors.
  • IM-3050 (FAP Radioligand Therapy) An FAP-targeted radioligand therapy designed to deliver radioactive lutetium-177 directly to FAP-expressing cancer-associated fibroblasts in solid tumors. Incorporates small molecule FAP-specific ligand with albumin-binding domain for improved tumor retention. FAP expressed in approximately 75% of solid tumors.
  • IM-1617 (Solid Tumor ADC) An ADC targeting an undisclosed receptor tyrosine kinase preferentially expressed in solid tumors including colorectal cancer, breast, ovarian, and non-small cell lung cancer. Mediates immune cell exclusion providing secondary mechanism of action. In Phase 1 trial.
  • IM-1340 (Solid Tumor ADC Candidate) An ADC targeting a transport receptor with unique tumor expression profile spanning neuroendocrine tumors and other solid tumors. Demonstrated robust preclinical efficacy with regressions following single dose in tumor models.
  • IM-1335 (Solid Tumor ADC Candidate) A potential best-in-class ADC for solid tumors designed to overcome limitations of a prior discontinued ADC against the same target. Shows efficacy in preclinical models with TOP1 payload class toxicity profile in non-human primates.

Quantifiable outcome

  • 84% reduction in risk of disease progression or death (HR=0.16, p<0.0001) vs placebo in Phase 3 RINGSIDE trial for desmoid tumors
  • +5 more outcomes

Companies that use Immunome

Customer profile

Named customers1 record

Segments3 records

Ideal customer profiles2 records

Immunome technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

Immunome partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Atreca, Inc.coreStrategic or Co-development Partner · 20 May 2024Immunome completed purchase of antibodies and related assets from Atreca, Inc. for $5.5 million upfront with additional milestone payments possible. Acquisition includes 28 antibodies and related materials enhancing Immunome's targeted cancer therapy portfolio. This acquisition was announced December 2023 and closed in May 2024.

Scale indicators10 records

Recent moves7 records

Expansion highlights7 records

Immunome competitors and assessment

Company assessment

Direct peers

  • Mersana Therapeutics: Clinical-stage ADC developer using proprietary payload platforms (Dolasynthen, Afucosylated antibodies) to target solid tumors. Directly comparable in business model, stage, and therapeutic focus on differentiated ADC payloads.
  • Olema Oncology: Clinical-stage oncology biotech developing targeted therapies for women's cancers. Kinney Horn (Immunome's CBO) was previously CBO at Olema, and both companies share similar size, stage, and capital markets profile as small-cap clinical oncology developers.
  • MacroGenics: Clinical-stage oncology biotech developing antibody-based therapeutics including ADCs and bispecifics. Bob Lechleider (Immunome's CMO) previously held roles at MacroGenics, and both companies pursue similar solid tumor ADC targets.

Broad incumbents

  • Telix Pharmaceuticals: Commercial-stage radiopharmaceutical company with multiple approved products (Illuccix) and a pipeline of radioligand therapies. Comparable in the therapeutic radiopharmaceutical category, though with greater scale and geographic reach.
  • Lantheus Holdings: Radiopharmaceutical company with commercial products (Pylarify, Definity) and a pipeline of targeted radioligand therapies. Comparable as a more established player in the same radiopharmaceutical oncology space as Immunome's IM-3050.
  • Seagen (acquired by Pfizer): Seagen developed and commercialized ADCETRIS, PADCEV, and TIVDAK, and was acquired by Pfizer for $43B in 2023. Immunome's leadership team and technology platform have direct lineage from Seagen, making it the closest functional and organizational peer.
  • ImmunoGen (acquired by AbbVie): ADC-focused biotech acquired by AbbVie for $10.1B in 2024. Developed Elahere (mirvetuximab soravtansine), the first FDA-approved ADC for ovarian cancer. Comparable as a specialist ADC developer with commercialized products in oncology.
  • Point Biopharma (acquired by Eli Lilly): Radiopharmaceutical company acquired by Eli Lilly for $1.4B in 2023, developing targeted radioligand therapies for cancer. Directly comparable to Immunome's IM-3050 FAP-targeted radioligand therapy program in technology category.
  • Daiichi Sankyo: Japanese pharmaceutical leader with a major ADC franchise (Enhertu, Datroway) developed in partnership with AstraZeneca. Comparable as a major ADC innovator targeting solid tumors with TOP1-payload technology, though at substantially greater scale.

Emerging players

  • Molecular Templates: Clinical-stage oncology company developing engineered toxin bodies (ETBs) for cancer treatment. Jack Higgins (Immunome's CSO) previously spent 11 years at Molecular Templates as Chief Development Sciences Officer, providing direct organizational overlap.

Market position

Strengths3 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Immunome social profiles

Digital presence

Immunome financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Immunome leadership team

Management profile

Number of profiles

Profiles8 records

Immunome funding detail

Funding detail

Funding overview

Funding rounds22 records

Investors11 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Immunome M&A and investment

M&A and investment

M&A2 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Immunome

What does Immunome do?

Immunome is a clinical-stage oncology company developing a portfolio of targeted cancer therapies, including antibody-drug conjugates (ADCs), radioligand therapies, and small molecule gamma-secretase inhibitors. Lead asset varegacestat (AL102) targets desmoid tumors with NDA accepted by the FDA, while pipeline programs (IM-1021, IM-3050, IM-1617, IM-1340, IM-1335) target various solid tumor antigens including ROR1 and FAP.

Is Immunome a public or private company?

Immunome is a public company. It is classified as public and is currently operating.

When was Immunome founded?

Immunome was founded in 2020. It employs 251 to 500 people.

Where is Immunome based?

Immunome is headquartered in Bothell, United States, in the North America region.

How does Immunome make money?

Two revenue lines are on record. Pharmaceutical Product Sales are the primary driver. The others are asset Acquisition Income.

Who are Immunome's main competitors?

Direct peers on record are Mersana Therapeutics, Olema Oncology and MacroGenics. Broad incumbents are Telix Pharmaceuticals, Lantheus Holdings, Seagen (acquired by Pfizer), ImmunoGen (acquired by AbbVie), Point Biopharma (acquired by Eli Lilly) and Daiichi Sankyo. Molecular Templates is listed as an emerging player.

Does Immunome have an API?

No public API is recorded for Immunome.

What industry is Immunome in?

Immunome's product category is Oncology Therapeutics. Its primary akta.pro industry code is HLAAAAAE, Antibody-Drug Conjugates (ADCs) & Antibody Conjugates, with a secondary code of HLAAAIAB, Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering). Its NAICS code is 325414 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
American Banking and Market NewsImmunome (NASDAQ:IMNM) Stock Price Target Cut by Piper SandlerPiper Sandler cut Immunome's price target from $33 to $30, keeping an overweight rating. The stock opened at $19.07, with a consensus price target of $33.85 and a Moderate Buy rating. Immunome reported a third-quarter loss of $0.76 per share, missing estimates.American Banking and Market NewsStifel Nicolaus Has Lowered Expectations for Immunome (NASDAQ:IMNM) Stock PriceStifel Nicolaus lowered its Immunome price target from $24 to $23, keeping a Hold rating. Piper Sandler also cut its target from $33 to $30, while the consensus remains a Moderate Buy at $33.85. Immunome reported a third-quarter loss of $0.76 per share, missing estimates.Defense WorldImmunome (NASDAQ:IMNM) Stock Price Target Lowered at Stifel NicolausStifel Nicolaus lowered its price target on Immunome from $24.00 to $23.00, keeping a hold rating. The stock opened at $18.65, with an average analyst rating of Moderate Buy and a price target of $33.85. The company reported a quarterly loss of $0.76 per share, missing estimates.Simply Wall StDoes Regulatory Progress Change The Bull Case For Immunome Stock (IMNM)?Immunome reported a Q3 2026 net loss of $85.78 million and advanced its oncology pipeline, with varegacestat's EU regulatory review underway. The company filed new shelf registrations for equity, debt, and warrants, including up to $82.8 million. Analysts project $306.2 million revenue by 2029, implying an 88% upside.American Banking and Market News36,062 Immunome, Inc. $IMNM Shares Bought by Alps Advisors Inc.Alps Advisors increased its Immunome stake by 31.5% in Q3, buying 36,062 shares to own 150,502 shares worth $3.237 million. Analysts rate the stock a Moderate Buy with an average target of $34.25, while the company reported a Q3 loss of $0.76 per share.American Banking and Market NewsImmunome, Inc. $IMNM Position Trimmed by Candriam S.C.A.Candriam S.C.A. trimmed its Immunome position by 28% in Q3, selling 190,279 shares and holding 489,853 shares. Analysts have a consensus "Moderate Buy" rating with an average price target of $34.25. Immunome reported a Q3 loss of $0.76 per share, missing estimates.The future of tradingImmunome Grants 206,700 Stock Options, 103,350 RSUs to 17 New EmployeesImmunome granted equity awards to 17 new employees on November 2, 2026, under its 2024 Inducement Plan. The awards include 206,700 stock options and 103,350 restricted stock units, both vesting over four years with 25% on the first anniversary and the balance monthly or annually thereafter.Investing.comImmunome stock may move 9.4% on earnings releaseImmunome Inc. is set to report earnings on Nov. 13, with options data suggesting a 9.4% stock move. The release time has not been confirmed. The company's stock has historically moved more than the options-implied amount in two of the past eight earnings announcements.FinancialContent Business PageImmunome to Present at Guggenheim 3rd Annual Healthcare Innovation ConferenceImmunome, Inc. will present at the Guggenheim 3rd Annual Healthcare Innovation Conference on November 10, 2026, at 9 a.m. EST. The live audio webcast will be available on the company's Investor Relations page, with a replay for about 30 days.MarketBeatImmunome, Inc. (IMNM) - What Are Researchers Saying About This Stock?Immunome, Inc. has a consensus 'Moderate Buy' rating from fifteen analysts, with an average price target of $34.25. Insiders sold 223,368 shares over the past ninety days, and the company missed Q2 EPS estimates at -$0.65 versus -$0.51 expected.